The Editor's Roundtable: Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk

  • Vincent E. Friedewald Jr.
    Correspondence
    Corresponding author: Tel: 512-264-1611; fax 512-264-7034
    Affiliations
    Assistant Editor, The American Journal of Cardiology, Clinical Professor, Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, and Research Professor, College of Science, University of Notre Dame, Notre Dame, Indiana
    Search for articles by this author
  • Joel S. Bennett
    Affiliations
    Professor of Medicine and Professor of Pharmacology, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    Search for articles by this author
  • Milton Packer
    Affiliations
    Gayle and Paul Stoffel Distinguished Chair in Cardiology, Professor and Chair, Department of Clinical Sciences, University of Texas Southwestern Medical School at Dallas, Dallas, Texas
    Search for articles by this author
  • William C. Roberts
    Affiliations
    Editor-in-Chief, The American Journal of Cardiology and Baylor University Medical Center Proceedings, Executive Director, Baylor Heart and Vascular Institute, Baylor University Medical Center, and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas, Texas
    Search for articles by this author
  • Gary W. Williams
    Affiliations
    Chairman, Department of Medicine, Immediate Past Chief, Division of Rheumatology, Scripps Clinic Medical Group, and Vice President, Medicine Services, Scripps Clinic Foundation, La Jolla, California
    Search for articles by this author
      This CME activity is supported by an educational grant from Pfizer, New York, New York.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mukherjee D.
        • Nissen S.E.
        • Topol E.J.
        Risk of cardiovascular events associated with selective COX-2 inhibitors.
        JAMA. 2001; 286: 954-959
        • McGettigan P.
        • Henry D.
        Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
        JAMA. 2006; 296: 1633-1644
        • Solomon D.H.
        • Schneeweiss S.
        • Glynn R.J.
        • Kiyota Y.
        • Levin R.
        • Mogun H.
        • Avorn J.
        Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
        Circulation. 2004; 109: 2068-2073
        • Levesque L.E.
        • Brophy J.M.
        • Zhang B.
        The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.
        Ann Intern Med. 2005; 142: 481-489
        • Graham D.J.
        • Campen D.
        • Hui R.
        • Spence M.
        • Cheetham C.
        • Levy G.
        • Shoor S.
        • Ray W.A.
        Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
        Lancet. 2005; 365: 475-481
        • Bombardier C.
        • Laine L.
        • Reicin A.
        • Shapiro D.
        • Burgos-Vargas R.
        • Davis B.
        • Day R.
        • Ferraz M.B.
        • Hawkey C.J.
        • Hochberg M.C.
        • et al.
        • VIGOR Study Group
        Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
        N Engl J Med. 2000; 343: 1520-1528
        • Bresalier R.S.
        • Sandler R.S.
        • Quan H.
        • Bolognese J.A.
        • Oxenius B.
        • Horgan K.
        • Lines C.
        • Riddell R.
        • Morton D.
        • Lanas A.
        • et al.
        • Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
        Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
        N Engl J Med. 2005; 352: 1092-1102
        • Nussmeier N.A.
        • Whelton A.A.
        • Brown M.T.
        • Langford R.M.
        • Hoeft A.
        • Parlow J.L.
        • Boyce S.W.
        • Verburg K.M.
        Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
        N Engl J Med. 2005; 352: 1081-1091
        • Solomon S.D.
        • McMurray J.J.
        • Pfeffer M.A.
        • Wittes J.
        • Fowler R.
        • Finn P.
        • Anderson W.F.
        • Zauber A.
        • Hawk E.
        • Bertagnolli M.
        • Adenoma Prevention with Celecoxib (APC) Study Investigators
        Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
        N Engl J Med. 2005; 352: 1071-1080
        • Solomon S.D.
        • Pfeffer M.A.
        • McMurray J.J.
        • Fowler R.
        • Finn P.
        • Levin B.
        • Eagle C.
        • Hawk E.
        • Lechuga M.
        • Zauber A.G.
        • et al.
        • APC and PreSAP Trial Investigators
        Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
        Circulation. 2006; 114: 1028-1035
        • Kearny P.M.
        • Baigent C.
        • Godwin J.
        • Halls H.
        • Emberson J.R.
        • Patrono C.
        Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?.
        BMJ. 2006; 332: 1302-1308
        • Cleveland Clinic Foundation Heart Center
        Cleveland Clinic launches large-scale global trial to examine cardiovascular safety of popular pain relievers.
        (Accessed July 25, 2008)
        • Bresalier R.S.
        • Friedewald V.E.
        • Rakel R.E.
        • Roberts W.C.
        • Williams G.W.
        The Editor's Roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk.
        Am J Cardiol. 2005; 96: 1589-1604
        • Belanger C.
        • Buring J.E.
        • Cook N.
        • Eberlein K.
        • Goldhaber S.Z.
        • Gordon D.
        • Hennekens C.H.
        • Mayrent S.L.
        • Peto R.
        • Rosner B.
        • et al.
        The Steering Committee of the Physicians' Health Study Research Group.
        N Engl J Med. 1989; 321: 129-135
        • Antman E.M.
        • Bennett J.S.
        • Daugherty A.
        • Furberg C.
        • Roberts H.
        • Taubert K.
        Use of nonsteroidal anti-inflammatory drugs.
        Circulation. 2007; 115: 1634-1642
        • United States Food and Drug Administration
        2006 safety alerts for drugs, biologics, medical devices, and dietary supplements: ibuprofen and aspirin taken together.
        (Accessed July 25, 2008)
        • Pfizer
        Pfizer for professionals.
        (Accessed July 25, 2008)
        • Griffin M.R.
        • Brandt K.D.
        • Liang M.H.
        • Pincus T.
        • Ray W.A.
        Practical management of osteoarthritis: integration of pharmacologic and nonpharmacologic measures.
        Arch Fam Med. 1995; 4: 1049-1055
        • Curhan G.C.
        • Knight E.L.
        • Rosner B.
        • Hankinson S.E.
        • Stampfer M.J.
        Lifetime nonnarcotic analgesic use and decline in renal function in women.
        Arch Intern Med. 2004; 164: 1519-1524
        • Chandrasekharan N.V.
        • Dai H.
        • Roos K.L.
        • Evanson N.K.
        • Tomsik J.
        • Elton T.S.
        • Simmons D.L.
        COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.
        Proc Natl Acad Sci U S A. 2002; 99: 13926-13931
        • Silverstein F.E.
        • Faich G.
        • Goldstein J.L.
        • Simon L.S.
        • Pincus T.
        • Whelton A.
        • Makuch R.
        • Eisen G.
        • Agrawal N.M.
        • Stenson W.F.
        • et al.
        Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial.
        JAMA. 2000; 284: 1247-1255